Discussion {#s1}
==========

AA is a steroidal inhibitor of 17α hydroxylase/C17,20-lyase (CYP17), which, in combination with prednisone, is approved for the treatment of mCRPC, based on the results of two randomized phase III trials demonstrating improvements in survival \[[@B1], [@B2]\]; but black men were largely underrepresented in both. Although poor access to health care is related to inferior outcomes in black men with prostate cancer, at least in part, differences in disease biology may also impact treatment response and survival. Indeed, germline polymorphisms in androgen metabolism genes (AMGs) have been correlated with response to androgen deprivation therapy \[[@B3], [@B4]\], and several AMG polymorphisms have been demonstrated to be more common in black patients, including polymorphisms in CYP17 \[[@B5]\].

This investigation was designed as a pilot study with a primary objective of determining whether there is a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA level of ≥30%) in black patients with mCRPC treated with abiraterone acetate. Specifically, germline polymorphisms (as determined from baseline peripheral blood samples) in *CYP17* and other genes involved in androgen metabolism were to be evaluated. Because this was the first prospective study, to our knowledge, to explore the relationship of germline polymorphisms in androgen pathway genes with response to hormonal therapy in a prospective cohort of black patients with CRPC, the study was designed to be exploratory, hypothesis generating, and to inform the design of larger, more definitive studies.

The primary endpoint of the study was to correlate germline polymorphisms in AMGs to a post-treatment decline in PSA level of ≥30%. Unfortunately, the study was prematurely terminated due to poor accrual, precluding the planned pharmacogenetic analyses. Of 10 evaluable patients treated, 9 had a ≥30% decline in PSA level. Treatment was generally well tolerated, with no subjects discontinuing treatment because of adverse effects. Treatment was generally well tolerated, with no subjects discontinuing treatment because of adverse effects, although incidence of some common adverse effects may have been higher than expected due to small sample size (e.g., fatigue).

To our knowledge, this is the first prospective interventional study exploring a treatment for mCRPC specifically enrolling black men; the study highlights several important lessons. Poor enrollment of black men in prostate cancer clinical trials is likely multifactorial: Black men are more often deemed ineligible for cancer clinical trials and are more likely to refuse participation when eligible \[[@B6], [@B7]\]. Despite opening our study at two centers with catchment areas made up of a large black population, these factors likely contributed to the poor accrual. Although it did not impact our study, increased use of multinational sites with very small black populations in phase III trials has further exacerbated disparities. Potential solutions include large multicenter postmarketing registries, patient navigation and community education, and dedicated clinical trials enrolling black patients \[[@B6], [@B8]\]. Although funding for multicenter investigator-initiated studies is often prohibitive, the National Cancer Institute cooperative group system may be an appropriate venue for such studies.

Trial Information {#s2}
=================

DiseaseProstate cancerStage of disease/treatmentMetastatic/advancedPrior therapyNo designated number of regimensType of study - 1Phase IIType of study - 2Single ArmPrimary EndpointOverall response rateSecondary EndpointEfficacySecondary EndpointCorrelative endpointSecondary EndpointSafetyAdditional Details of Endpoints or Study DesignThe primary objective of this study was to determine a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA of ≥30%) in black patients with castration-resistant prostate cancer treated with abiraterone acetate. Specifically, germline polymorphisms (as determined from baseline peripheral blood samples) in *CYP17* and other genes involved in androgen metabolism will be evaluated---a total of approximately 120 polymorphisms tagging all known, common variations across 20 genes of interest.Unfortunately, the study was prematurely terminated due to poor accrual, precluding the planned pharmacogenetic analyses. Of 10 evaluable patients treated, 9 had a ≥30% PSA decline.Investigator\'s AnalysisActive but results overtaken by other developments

Drug Information {#s3}
================

Drug 1Generic/Working nameAbiraterone acetateTrade nameZytigaCompany nameJanssen BiotechDrug typeBiologicalDrug classAndrogen receptorDose1,000 mg per flat doseRouteOralSchedule of AdministrationTake 1,000 mg every morning on an empty stomachDrug 2Generic/Working namePrednisoneDrug classCorticosteroidDose5 mg, twice daily, per flat doseRouteOral

Patient Characteristics {#s4}
=======================

Number of patients, male11Number of patients, female0StageStage IV, castration-resistant prostate cancerAgeMedian (range): 66 (54--78)Number of prior systemic therapiesMedian (range): 3 (1--4)Performance Status: ECOG0 --- 81 --- 32 ---3 ---Unknown ---Cancer Types or Histologic SubtypesAdenocarcinoma of the prostate 11

Primary Assessment Method {#s5}
=========================

Control Arm: Adenocarcinoma of the ProstateNumber of patients screened11Number of patients enrolled11Number of patients evaluable for toxicity10Number of patients evaluated for efficacy10Response assessment PR*n* = 9 (90)Response assessment SD*n* = 1 (10)

 {#s6}

Control Arm: Total Patient PopulationNumber of patients screened11Number of patients enrolled11Number of patients evaluable for toxicity10Number of patients evaluated for efficacy10Response assessment PR*n* = 9 (90)Response assessment SD*n* = 1 (10)

Adverse Events {#s7}
==============

Assessment, Analysis, and Discussion {#s8}
====================================

CompletionStudy terminated before completionTerminated reasonDid not fully accruePharmacokinetics/PharmacodynamicsNot collectedInvestigator\'s AssessmentEndpoint not met because study closed early due to poor accrual.

Abiraterone acetate (AA) is a steroidal inhibitor of 17α hydroxylase/C17,20-lyase (CYP17), which, in combination with prednisone, is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC), based on the results of 2 randomized phase III trials demonstrating improvements in survival \[[@B1], [@B2]\]; but black men were largely underrepresented in both. Although poor access to health care is related to inferior outcomes in black men with prostate cancer, at least in part, differences in disease biology may also impact treatment response and survival. Indeed, germline polymorphisms in androgen metabolism genes (AMGs) have been correlated with response to androgen deprivation therapy \[[@B3], [@B4]\], and several AMG polymorphisms have been demonstrated to be more common in black patients, including polymorphisms in CYP17 \[[@B5]\].

This investigation was designed as a pilot study with a primary objective of determining whether there is a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a ≥30% decline in prostate-specific antigen \[PSA\] level) in black patients with mCRPC treated with abiraterone acetate. Specifically, germline polymorphisms (as determined from baseline peripheral blood samples) in CYP17 and other genes involved in androgen metabolism were to be evaluated. Because this was the first prospective study, to our knowledge, to explore the relationship of germline polymorphisms in androgen pathway genes with response to hormonal therapy in a prospective cohort of black patients with CRPC, the study was designed to be exploratory, hypothesis generating, and to inform the design of larger more definitive studies.

The primary endpoint of the study was to correlate germline polymorphisms in AMGs to a post-treatment decline in PSA level of ≥30%. Unfortunately, the study was prematurely terminated due to poor accrual, precluding the planned pharmacogenetic analyses. Of 10 evaluable patients treated, 9 had a ≥30% decline in PSA level ([Fig. 1](#F1){ref-type="fig"}). Treatment was generally well tolerated, with no subjects discontinuing treatment because of adverse effects, although incidence of some common adverse effects may have been higher than expected due to small sample size (e.g., fatigue).

![Waterfall plot of maximum post-treatment declines in prostate-specific antigen levels.](theoncologist_16026CTR_f1){#F1}

To our knowledge, this was the first prospective interventional study exploring a treatment for mCRPC specifically enrolling black men and it highlights several important lessons. Poor enrollment of black men in prostate cancer clinical trials is likely multifactorial: Black men are more often deemed ineligible for cancer clinical trials and are more likely to refuse participation when eligible \[[@B6], [@B7]\]. Despite opening our study at two centers with catchment areas made up of a large black population, these factors likely contributed to the poor accrual. Although it did not impact our study, increased use of multinational sites with very small black populations in phase III trials has further exacerbated disparities. Potential solutions include large multicenter postmarketing registries, patient navigation and community education, and dedicated clinical trials enrolling black patients \[[@B6], [@B8]\]. Although funding for multicenter investigator-initiated studies is often prohibitive, the National Cancer Institute cooperative group system may be an appropriate venue for such studies.

[**ClinicalTrials.gov**](http://ClinicalTrials.gov) **Identifier:** [NCT01735396](https://clinicaltrials.gov/ct2/show/NCT01735396)

**Sponsor:** Janssen Biotech

**Principal Investigator:** Matthew David Galsky

**IRB Approved:** Yes

[Click here](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results) to access other published clinical trials.

**EDITOR\'S NOTE:** See the related commentary, "The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?," by Jonathan D. Jackson, Beverly Moy, and Michele K. Evans, on page [1411](10.1634/theoncologist.2016-0327) of this issue.
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